Physician profile
Fernando Davalos
NPI 1578765848
$5,764.64
in general payments reported to CMS, 2019-2025
38 companies · $813 in 2025
The $813 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $820 · 2021: $543 · 2022: $1,083 · 2023: $702 · 2024: $1,155 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,103.96 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $898.09 | 2019-2025 | Ubrelvy, Qulipta, Creon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.04 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $450.83 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $411.51 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $408.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $352.69 | 2019-2024 | |
| Amgen INC. | $202.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $183.42 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $163.47 | 2019-2021 | |
| Abbott Laboratories | $126.82 | 2023-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $122.07 | 2019 | |
| Cleerly, INC. | $109.53 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Teva Pharmaceuticals USA, INC. | $74.18 | 2022-2024 | Ajovy, Austedo Xr, Austedo |
| Dexcom, INC. | $69.58 | 2024-2025 | Dexcom G6 Transmitter |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Davalos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.